<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01842542</url>
  </required_header>
  <id_info>
    <org_study_id>44-03014-000</org_study_id>
    <nct_id>NCT01842542</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of NeuroStar TMS Therapy in Patients With Major Depressive Disorder With Postpartum Onset</brief_title>
  <official_title>An Open-Label Study to Evaluate the Efficacy and Safety of the Neuronetics NeuroStar TMS Therapy System in Patients With Major Depressive Disorder (MDD) With Postpartum Onset.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuronetics</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuronetics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of acute NeuroStar TMS&#xD;
      therapy in women who have postpartum depression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate the antidepressant effectiveness of acute treatment with NeuroStar TMS Therapy in&#xD;
      patients with MDD with postpartum onset.&#xD;
&#xD;
      Determine the safety of NeuroStar TMS Therapy by assessment of any medically significant,&#xD;
      device-related adverse events during acute treatment.&#xD;
&#xD;
      Determine the Safety of NeuroStar TMS Therapy by assessment of maternal and infant&#xD;
      interactions on standardized bonding questionnaires.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the antidepressant effectiveness of acute treatment with NeuroStar TMS Therapy in patients with MDD with postpartum onset</measure>
    <time_frame>up to 8 weeks.</time_frame>
    <description>Acute NeuroStar TMS treatment of 5 days per week for upto 8 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the safety of NeuroStar TMS Therapy.</measure>
    <time_frame>upto 8 weeks plus 3 week taper.</time_frame>
    <description>Medically significant, device related adverse events will be collected during the acute and taper phase.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Determine the safety of NeuroStar TMS Therapy by assessment of maternal and infant interactions on standardized bonding questionnaires.</measure>
    <time_frame>Up to 8 weeks plus 3 week taper.</time_frame>
    <description>Patients complete questionnaires during the acute and taper treatment phase at protocol specific timepoints.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Depression, Postpartum</condition>
  <arm_group>
    <arm_group_label>Transcranial Magnetic Stimulation (TMS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive NeuroStar Transcranial Magnetic Stimulation (TMS) therapy treatments 5 times a week for up to 8 weeks during the acute phase, 3 times during the first week, 2 times during the second week and 1 time during the third week of the taper phase.&#xD;
Efficacy Assessments will be conducted throughout the acute and taper phase at protocol specific timepoints.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeuroStar Transcranial Magnetic Stimulation (TMS)</intervention_name>
    <description>Acute phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, five times weekly for up to 8 weeks.&#xD;
3 week taper phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, 3 times during the first week, 2 times during the second week and one time during the third week. In addition to treatments, patients may receive treatment as usual at the direction of their treating physician.</description>
    <arm_group_label>Transcranial Magnetic Stimulation (TMS)</arm_group_label>
    <other_name>NeuroStar TMS Therapy Treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female outpatients, 18 to 50 years of age.&#xD;
&#xD;
          -  Diagnosis of DSM-IV defined Major Depressive Disorder, single or recurrent episode,&#xD;
             with current episode duration of at least 2 weeks.&#xD;
&#xD;
          -  Onset and duration of current illness within 6 months of live childbirth.&#xD;
&#xD;
          -  HAMD17 total score of greater than or equal to 18 and a score on the Edinburgh&#xD;
             Postnatal Depression scale (EPDS) greater than or equal to 10.&#xD;
&#xD;
          -  Patient cannot be on an antidepressant or other psychotropic medications during the&#xD;
             study.&#xD;
&#xD;
          -  Capable and willing to provide informed consent.&#xD;
&#xD;
          -  Signed HIPAA authorization.&#xD;
&#xD;
          -  Able to adhere to the treatment schedule.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals diagnosed by the Investigator with the following conditions (current&#xD;
             unless otherwise stated): Depression secondary to a general medical condition, or&#xD;
             substance-induced Seasonal pattern of depression as defined by DSM-IV;History of&#xD;
             substance abuse or dependence within the past year(except nicotine and caffeine);Any&#xD;
             psychotic disorder (lifetime), including schizoaffective disorder, or major depression&#xD;
             with psychotic features in this or previous episodes;Bipolar disorder;Eating disorder&#xD;
             (current or within the past year);Obsessive compulsive disorder (lifetime); or&#xD;
             Post-traumatic stress disorder (current or within the past year).&#xD;
&#xD;
          -  Individuals with a clinically defined neurological disorder or insult including, but&#xD;
             not limited to:Any condition likely to be associated with increased intracranial&#xD;
             pressure;Space occupying brain lesion;History of cerebrovascular accident;Transient&#xD;
             ischemic attack within two years; Cerebral aneurysm; Dementia;Parkinson's&#xD;
             disease;Huntington's chorea;Multiple sclerosis.&#xD;
&#xD;
          -  History of treatment with Vagus Nerve Stimulation.&#xD;
&#xD;
          -  History of failure to respond to an adequate course of ECT treatment.&#xD;
&#xD;
          -  Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable&#xD;
             cardiac disease.&#xD;
&#xD;
          -  Intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or&#xD;
             electrodes) or any other metal object within or near the head, excluding the mouth,&#xD;
             that cannot be safely removed.&#xD;
&#xD;
          -  Women of child-bearing potential not using a medically accepted form of contraception&#xD;
             when engaging in sexual intercourse.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Brock, MD</last_name>
    <role>Study Director</role>
    <affiliation>Neuronetics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hartford Hospital Institute of Living</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Health Adult Psychiatry - Springhill</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harmonex Neuroscience and Research of Pensacola</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrative Psychiatry</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TMS Medical Associates of NY</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TMS Center of Lehigh Valley</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah - Neuropsychiatric Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 19, 2013</study_first_submitted>
  <study_first_submitted_qc>April 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2013</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postpartum Depression, NeuroStar TMS Therapy, TMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression, Postpartum</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

